0855 GMT - Sanofi shares fall in European morning trading, while Regeneron Pharmaceuticals is sharply lower in U.S. premarket trading, after the companies reported mixed results from two late-stage trials of a respiratory drug they are jointly developing. Sanofi and Regeneron said drug candidate Itepekimab missed the key goal of a phase 3 trial, but met the primary objective in the other study. Paris-listed shares in Sanofi fall 5.8%, while Regeneron shares drop 12% in U.S. premarket trading. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
May 30, 2025 04:56 ET (08:56 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.